Truist raised the firm’s price target on Sabra Health Care (SBRA) to $18 from $17 and keeps a Hold rating on the shares. The risk of recession has increased and the 10-year Treasury rate has fallen since the firm’s downgrade of the stock in January, the analyst tells investors in a research note. Notwithstanding risks to Medicaid funding, select healthcare REITs might generally be relatively defensive within the sector if macroeconomic trends continue to worsen, Truist adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Healthcare Reit Projects Positive 2025 Amid Growth
- Sabra Healthcare REIT Reports Strong Q4 2024 Results
- Sabra Healthcare REIT: Hold Rating Amid Stable Financials and Cautious Growth Strategy
- Sabra Health Care reports Q4 AFFO 36c, consensus 36c
- Sabra Health Care sees FY25 AFFO $1.47-$1.50, consensus $1.49